Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure

• Status: Terminated
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with advanced cirrhosis have abnormal translocation of Gram-negative bacteria across the intestinal barrier and subsequent systemic inflammatory response. We hypothesized that this translocation may worsen the underlying liver disease. Thus, the aim of this trial was to assess the effects of the oral administration of norfloxacin (an antibiotic that suppresses intestinal Gram-negative bacteria) on the development of complications of cirrhosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Norfloxacin

Criteria

Inclusion Criteria:

• Age > 18 years,

• Liver failure as defined by a Child-Pugh score ≥ 10 points,

• Accept to participate,

• Have health insurance.

Exclusion Criteria:

• Pregnancy,

• Patient who has been treated with a quinolone in the month before his inclusion

• Allergy to quinolones,

• Hepatocellular carcinoma, and

• HIV infection.